TY - JOUR
T1 - Nephrogenic Systemic Fibrosis in Patients with Chronic Kidney Disease after the Use of Gadolinium-Based Contrast Agents
T2 - A Review for the Cardiovascular Imager
AU - Gallo-Bernal, Sebastian
AU - Patino-Jaramillo, Nasly
AU - Calixto, Camilo A.
AU - Higuera, Sergio A.
AU - Forero, Julian F.
AU - Lara Fernandes, Juliano
AU - Góngora, Carlos
AU - Gee, Michael S.
AU - Ghoshhajra, Brian
AU - Medina, Hector M.
N1 - Publisher Copyright:
© 2022 by the authors.
PY - 2022/8
Y1 - 2022/8
N2 - Gadolinium-enhanced cardiac magnetic resonance has revolutionized cardiac imaging in the last two decades and has emerged as an essential and powerful tool for the characterization and treatment guidance of a wide range of cardiovascular diseases. However, due to the high prevalence of chronic renal dysfunction in patients with cardiovascular conditions, the risk of nephrogenic systemic fibrosis (NSF) after gadolinium exposure has been a permanent concern. Even though the newer macrocyclic agents have proven to be much safer in patients with chronic kidney disease and end-stage renal failure, clinicians must fully understand the clinical characteristics and risk factors of this devastating pathology and maintain a high degree of suspicion to prevent and recognize it. This review aimed to summarize the existing evidence regarding the physiopathology, clinical manifestations, diagnosis, and prevention of NSF related to the use of gadolinium-based contrast agents.
AB - Gadolinium-enhanced cardiac magnetic resonance has revolutionized cardiac imaging in the last two decades and has emerged as an essential and powerful tool for the characterization and treatment guidance of a wide range of cardiovascular diseases. However, due to the high prevalence of chronic renal dysfunction in patients with cardiovascular conditions, the risk of nephrogenic systemic fibrosis (NSF) after gadolinium exposure has been a permanent concern. Even though the newer macrocyclic agents have proven to be much safer in patients with chronic kidney disease and end-stage renal failure, clinicians must fully understand the clinical characteristics and risk factors of this devastating pathology and maintain a high degree of suspicion to prevent and recognize it. This review aimed to summarize the existing evidence regarding the physiopathology, clinical manifestations, diagnosis, and prevention of NSF related to the use of gadolinium-based contrast agents.
KW - cardiac magnetic resonance
KW - chronic kidney disease
KW - gadolinium-based contrast agents
KW - nephrogenic systemic fibrosis
UR - http://www.scopus.com/inward/record.url?scp=85137385520&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85137385520&partnerID=8YFLogxK
U2 - 10.3390/diagnostics12081816
DO - 10.3390/diagnostics12081816
M3 - Review article
AN - SCOPUS:85137385520
SN - 2075-4418
VL - 12
JO - Diagnostics
JF - Diagnostics
IS - 8
M1 - 1816
ER -
